Skip to main content
. 2018 Feb 16;11:809–821. doi: 10.2147/OTT.S151867

Figure 2.

Figure 2

Establishment of L-OHP–resistant HCT-8 cell line.

Notes: (A–E) Cells were treated with various concentrations of L-OHP, 5-FU, CPT-11, VCR, and CDDP for 48 h and analyzed by MTT analyses. (F) IC50 values of the parental HCT-8 cells and HCT-8/L-OHP cells exposed to L-OHP, 5-FU, CPT-11, VCR, and CDDP. Data are presented as mean ± SD of triplicate experiments. *P<0.05, **P<0.01 versus HCT-8/L-OHP cells. (G) The mRNA expression of ABCC1, ERCC1, GSTP1, and ABCB1. ABCC1, ERCC1, and ABCB1 were increased in HCT-8/L-OHP cells. (H) The protein expressions of ABCC1, ERCC1, GSTP1, and ABCB1, and were increased in HCT-8/L-OHP cells. Data are presented as mean ± SD of triplicate experiments. *P<0.05, **P<0.01 versus HCT-8/L-OHP cells.

Abbreviations: L-OHP, oxaliplatin; 5-FU, 5-fluorouracil; CPT-11, irinotecan; VCR, vincristine; CDDP, cis-diamminedichloroplatinum; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.